A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis

Masashi Sawa, Toshihiro Miyamoto, Hee-Je Kim, Yasushi Hiramatsu, June-Won Cheong, Takayuki Ikezoe, Tomoki Naoe, Koichi Akashi, Satoshi Morita, Masanori Kosako, Masaki Shimura, Wataru Terada, Takeshi Kadokura, Jason Hill, Shuichi Miyawaki, Stanley C. Gill, Alexandra Heinloth, Nahla Hasabou

Therapeutic Advances in Hematology

Published online on March 12, 2026

Abstract

Therapeutic Advances in Hematology, Volume 17, January-December 2026.
Background:Mutations in theFMS-like tyrosine kinase 3 (FLT3) gene are present in approximately 30% of patients with newly diagnosed (ND) acute myeloid leukemia (AML), and are associated with worse therapy outcomes compared to the general AML population. ...